Director/PDMR Shareholding

RNS Number : 0273L

GlaxoSmithKline PLC

07 September 2021

 

GlaxoSmithKline plc   (the ' Company ')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the vesting on 4 September 2021 of 25% of an award made on 14 February 2018 under the GlaxoSmithKline Deferred Investment Award Programme, Mr Miels will receive a cash payment of £409,730.64 less applicable tax withholding in respect of 27,706.968 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.788	27,706.968
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2021-09-04
f)	Place of the transaction	N/A

 

END

 

 

DSHEDLFBFKLEBBB